Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY4636581
VERVE-102 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| VERVE-102 Dose 1 | EXPERIMENTAL | Participants will receive a single dose of VERVE-102 intravenously (IV) |
| VERVE-102 Dose 2 | EXPERIMENTAL | Participants will receive a single dose of VERVE-102 IV |
| VERVE-102 Dose 3 | EXPERIMENTAL | Participants will receive a single dose of VERVE-102 IV |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo IV |
| Cohort 1: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 2: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 3: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 4: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 5: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 6: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 7: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 8: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 9: Single Fixed Dose | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Cohort 10: Single Fixed Dose | EXPERIMENTAL | Participants will receive a single dose of VERVE-102. |
| Name | Type | Description |
|---|---|---|
| VERVE-102 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD Exclusion Criteria: * History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH) * Chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatme...
Top 10 of 16 competitors
VERVE-102 is an investigational therapy being developed for atherosclerosis and heterozygous familial hypercholesterolemia, conditions characterized by elevated cholesterol and cardiovascular risk. It is not yet approved for any indication and remains in clinical development.
VERVE-102 targets PCSK9, a protein that regulates LDL cholesterol levels. By targeting PCSK9, the therapy aims to lower cholesterol in patients with atherosclerosis or heterozygous familial hypercholesterolemia.
VERVE-102 is being developed by Verve Therapeutics, Inc., a biotechnology company focused on cardiovascular gene editing therapies. The company trades on the Nasdaq under the ticker symbol VERV.
VERVE-102 is in Phase 2 clinical development. A Phase 2 trial is planned but not yet recruiting, and a Phase 1 trial is currently recruiting participants. The therapy has not received regulatory approval.
VERVE-102 is being evaluated in two clinical trials. The Phase 2 trial, NCT07839936, will enroll 175 adults with or at high risk for cardiovascular disease in the United States. The Phase 1 trial, NCT06164730, is recruiting 85 patients with familial hypercholesterolemia or premature coronary artery disease across multiple countries.
Yes, VERVE-102 is also known as LY4636581. The Phase 2 trial listing refers to the therapy as VERVE-102 (LY4636581), confirming they are the same investigational compound.